LoginSignup
BTI logo

BTI Stock

StockStock
ISIN: US09075P1057
Ticker: BTAI
US09075P1057
BTAI

Price

Frequently asked questions

What is BTI's market capitalization?

The market capitalization of BTI is $29.33M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for BTI?

BTI's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.555. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for BTI's stock?

Currently, 4 analysts cover BTI's stock, with a consensus target price of $8.25. Analyst ratings provide insights into the stock's expected performance.

What is BTI's revenue over the trailing twelve months?

Over the trailing twelve months, BTI reported a revenue of $2.40M.

What is the EBITDA for BTI?

BTI's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$104.30M. EBITDA measures the company's overall financial performance.

What is the free cash flow of BTI?

BTI has a free cash flow of -$105.33M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of BTI's stock?

The 5-year beta for BTI is 0.24. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does BTI have, and what sector and industry does it belong to?

BTI employs approximately 74 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of BTI's shares?

The free float of BTI is 32.57M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $29.33M

5Y beta

 0.24

EPS (TTM)

 -$3.555

Free Float

 32.57M

Revenue (TTM)

 $2.40M

EBITDA (TTM)

 -$104.30M

Free Cashflow (TTM)

 -$105.33M

Pricing

1D span
$0.653$0.751
52W span
$0.505$4.891

Analyst Ratings

The price target is $8.25 and the stock is covered by 4 analysts.

Buy

3

Hold

1

Sell

0

Information

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

74

Biotechnology & Drugs

Health Care

Identifier

ISIN

US09075P1057

Primary Ticker

BTAI

Knockouts

Join the conversation
Sign upLogin